Mounjaro®
Starting from £179.99/mo
Start journey Learn morePhotos taken one month into Wegovy often show modest but real change — a slightly less bloated midsection, clothes sitting differently, a face that looks a little leaner. At the 2.5 mg starting dose, most people are still adjusting to the medicine, so dramatic one-month before-and-after pictures should be read with healthy scepticism. Wegovy is a prescription-only medicine licensed in the UK for weight management in adults; a prescriber assesses whether it is suitable for you before any treatment begins. The overview of Wegovy on this site covers the full picture, but if you want to understand specifically what is and is not realistic to see in early Wegovy before and after pictures at the one-month mark, the following is an honest, evidence-based account.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first pen delivers 0.25 mg once weekly. It is worth knowing that this dose was chosen specifically to reduce side effects, not to maximise fat loss. Within days, many people notice their appetite feels different: meals feel filling sooner, the mental pull towards food between mealtimes is quieter. These changes are real and clinically meaningful, but they do not yet translate into dramatic physical change. Most people lose between one and three kilograms in the first four weeks, though some lose more and some less, individual responses vary considerably depending on starting weight, diet and activity. A common misconception is that a slow first month means the medicine is not working; the early weeks are more about establishing tolerance than delivering measurable results, and the trajectory typically accelerates once the dose increases.
The NHS patient guidance on semaglutide confirms that the 0.25 mg starting dose is an introductory one, with the prescriber titrating upwards over subsequent months. Reading that guidance alongside any before and after pictures gives a much more grounded sense of what the photos are actually capturing.
By the end of the first month, some people do have photos that show a visible difference. Faces tend to show change earlier than torsos. Waistlines may look slightly less full, particularly if early weight loss has reduced water retention alongside fat. But a photograph is a limited document. Lighting, posture, clothing, time of day and how recently someone ate all affect what a one-month image looks like. The Wegovy before and after pictures that travel furthest online are the striking ones, which selects for outliers. People who lose four or five kilograms in the first month exist, but they are not the median experience. For a fuller sense of how results develop over time, three-month before and after pictures tend to be more representative of meaningful change.
It is also worth looking at results broken down by sex and body type. Patterns in female before and after Wegovy pictures can differ from aggregate trial data, partly because women and men tend to carry and lose weight differently.
The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks at the full 2.4 mg maintenance dose and recorded an average weight reduction of around 15%. That figure is spread across more than a year, not one month. What one-month data from that trial and related analyses suggests is that roughly a third of the eventual total loss typically occurs in the first twelve weeks, meaning the bulk of visible change comes later. The broader collection of Wegovy weight loss before and after pictures on this site contextualises that timeline clearly.
For people curious about how long the medicine takes to work in a more clinical sense, the page on how long Wegovy takes to work addresses the dose-by-dose trajectory in detail. And if you are weighing Wegovy against other injectable medicines, the semaglutide and B12 combination page explains a different clinical approach some providers use. The cost of a longer course of treatment is something many people ask about early on; the Wegovy price comparison page sets out what UK private pricing typically looks like across providers.
Starting weight matters. Someone beginning treatment at a higher BMI tends to see more absolute change early on, even if the percentage loss is similar to a lighter person. Adherence to the recommended dietary adjustments (smaller portions, reduced ultra-processed food) amplifies the medicine's appetite-lowering effect. Sleep, stress and how well-hydrated someone is also affect water retention, which is a real component of early weight change that does not always show in photos. Side effects in week one or two (nausea is the most commonly reported) sometimes reduce food intake so sharply that early results look striking, but this does not always persist as tolerance develops. A calmer, sustained reduction in appetite is generally a more reliable driver of long-term change. For anyone thinking about starting treatment, the weight loss treatment overview explains the options available and what a clinical assessment involves. Our clinical team reviews every consultation personally. Speak to our prescribers to understand what is realistic for your situation before month one even begins.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.